Spyre CFO Scott Burrows sells $716,771 in stock

uk.investing.com

Spyre Therapeutics CFO Scott Burrows sold $716,771 in company stock on August 3, 2026, following an option exercise, with shares trading near a 52-week high. Burrows disposed of 7,500 shares at prices from $95.21 to $97.10, after exercising options at $14.50 per share. The sales occurred under a Rule 10b5-1 plan; he retains 97,994 shares, including restricted units. The stock has risen 554% over the past year. Positive trial data for ulcerative colitis drug SPY002 prompted some analyst hikes, though a separate fund sold $399.7 million in shares.


With a significance score of 0.9, this news ranks in the top 77% of today's 33320 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Spyre CFO Scott Burrows sells $716,771 in stock | News Minimalist